Cart
sales@molnova.com
Home - Products - Autophagy - CCR - Plozalizumab

Plozalizumab

CAS No. 1610761-46-0

Plozalizumab( —— )

Catalog No. M36823 CAS No. 1610761-46-0

Plozalizumab (MLN-1202) is a humanized, selective, and potent anti-CCR2 antibody with antitumor activity, used in the study of malignant melanoma.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 565 Get Quote
5MG 943 Get Quote
10MG 1492 Get Quote
25MG 2144 Get Quote
50MG 2898 Get Quote
100MG 3825 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Plozalizumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Plozalizumab (MLN-1202) is a humanized, selective, and potent anti-CCR2 antibody with antitumor activity, used in the study of malignant melanoma.
  • Description
    Plozalizumab (MLN-1202) is a specific humanized anti-CCR2 antibody. Plozalizumab can be used for malignant melanoma research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Autophagy
  • Target
    CCR
  • Recptor
    CCR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1610761-46-0
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Jahchan NS, et al. Tuning the Tumor Myeloid Microenvironment to Fight Cancer. Front Immunol. 2019 Jul 25;10:1611.?
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • CCR3 antagonist 1

    CCR3 antagonist 1 is a potent CCR3 antagonist used in researching inflammatory and immunologic diseases.

  • CCR6 antagonist 1

    CCR6 antagonist 1, a chemical compound acting as a CCR6 antagonist, effectively inhibits the CCL20/CCR6 axis. Its utility lies in research focused on autoimmune-mediated inflammatory diseases, including inflammatory bowel diseases (IBDs).

  • CCR4 antagonist 3-1

    CCR4 antagonist 3-1 is a less active chemokine receptor 4 (CCR4) antagonist that inhibits [125I]TARC (thymus and activation-regulated chemokine) with an IC50 value of 1.7 μM.

Sign In Join Free